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Models have become a nearly essential component of health technology assessment. This is because 
the efficacy and safety data available from clinical trials are insufficient to provide the required 
estimates of impact of new interventions over long periods of time and for other populations and 
subgroups. Despite more than five decades of use of these decision-analytic models, decision makers 
are still often presented with poorly validated models and thus trust in their results is impaired. 
Among the reasons for this vexing situation are the artificial nature of the models, impairing their 
validation against observable data, complexity in their formulation and implementation, lack of data 
against which to validate the model results, and the challenges of short timelines and insufficient 
resources. This paper addresses this crucial problem of achieving models that produce results that 
can be trusted and the resulting requirements for validation and transparency, areas where our field 
is currently deficient. Based on their differing perspectives and experiences, the authors characterize 
the situation, outline requirements for improvement and pragmatic solutions to the problem of 
inadequate validation. 
Key points 
Although models are frequently used to inform health technology assessments, they tend to be 
poorly verified and largely unvalidated. This makes it difficult to trust their results. 
Validation of these models is challenging because there are few opportunities to check their results 
against applicable real-world observations. 
Practical steps to improved model validity include transitioning from bespoke to open-source models 
that leverage standard modules and detailed, transparent documentation of all aspects including 
steps taken to verify and validate the model.  
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1. Background & objective  
The decision-analytic model is an important tool for health technology assessment (HTA). These 
models have been used to extend the efficacy and safety information obtained from clinical trials to 
broader populations, time horizons and outcomes of interest (e.g. the quality-adjusted life year, 
QALY). Despite the extensive use of these decision-analytic models, their ability to predict the 
outcomes of interest in a reasonably accurate and unbiased way is usually unknown because it has 
not been assessed (i.e., validation) [1-2].. Moreover, these models are often constructed under 
severe time and other constraints and complexly formulated and, thus, it is very difficult to ensure 
that they perform as intended (i.e.,  verification) [3]. In part, this situation results from the lack of 
sufficient data to both populate the model and validate it [4], but with the increasing availability of 
large datasets this reason is diminishing. Nevertheless, the short timelines and unreasonable 
pressures to keep these models simple and transparent often impair their accuracy and usefulness 
[5]. 
In this opinion piece, we address the crucial topic of trusting the results of economic analyses based 
on decision analytic models. Based on our different perspectives and experiences, we characterize 
the situation leveraging a pilot study on the cost-effectiveness analyses (CEA) submitted to the 
French National Authority for Health (“Haute Autorité en Santé”, or HAS), as well as the experience 
of modeling experts, one providing services to the National Institute for Health and Care Excellence 
(NICE) through one of its independent Evidence Review Group (ERG), and another constructing 
models at a consulting company. We conclude by discussing the prospects for possible options to the 
problem of inadequate validation. 
2. What are the approaches to model validation? 
The ISPOR-SMDM Modeling Good Research Practices Task Force [1] proposes five important 
questions regarding model verification and validation: 
1. Is the model (its assumptions and structure) consistent with current knowledge on the 
question and the history and management of the pathology under study (face validity)? 
2. Has the model been verified to ensure it was technically implemented without errors 
(internal validity)?  
3. Do the outputs of the model correctly reflect the results provided by external (ideally 
independent) sources (external validity)? 
4. Does the model predict accurately what will be observed in ongoing studies (predictive 
validity)? 
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5. Does the model accord with other models that use other approaches to the problem (cross 
validity, noted to be potentially misleading as other models may also be invalid)? 
Current HTA guidelines reference these questions but without providing a practical framework for 
addressing them [2]. For example, the Canadian [6] and the NICE [7] guidelines recommend 
describing the validation undertaken, while the Belgian guidelines [8] insist on the importance of 
checking the model against other models for the same intervention and HAS guidelines [9] 
emphasize that a model should produce results that are “suitable” for decision-making. Australian 
and Dutch guidelines [10-11] do explicitly ask applicants to add structured reporting of model 
validation tests to their dossier using, for example, the Validation-Assessment Tool of Health-
Economic Models for Decision Makers and Model Users (AdViSHE) [12]. 
The following experiences with model validation show that these requirements are usually not 
fulfilled. 
3. Experiences with model validation 
3.1. The French pilot study 
In France, the process of economic evaluation of drugs and medical devices was implemented in 
October 2013 [13]. A pilot study was carried out in June 2017 to identify the main issues regarding 
validation of decision-analytic models [14]. Two health economists independently reviewed each of 
the 77 manufacturers’ CEAs received at HAS between 2013 and 2017.  Based on prior publications [1, 
15-16], validation in each one was classified as: neither undertaken nor discussed; undertaken, but 
not discussed; not undertaken but discussed; undertaken and discussed. Of the 77, 45% were in 
oncology, 17% in infectious disease; 13% in cardiology and 25% in other therapeutic areas. Generally, 
there was a lack of a validation plan or statistical rationale including, for example, a transparent 
documentation of any attempts to adjust model parameters to fit particular known outcomes (i.e., 
calibration). Less than 50% reported a validation process and only 35% performed any external 
validation. These results were similar to those obtained in a comprehensive literature review [15].  
This pilot study highlighted that finding a balance between building trustworthy models and the 
resource constraints and national regulatory deadlines is a challenge, especially for HTA agencies 
where appraisals are done within the organization. The paucity of model validation among those 77 
submissions suggests that this is a difficult step, perhaps because it takes additional time to complete 
and requires finding external experts without conflicts of interest. By contrast with verification, 
external validation remains a major concern as it is not possible to externally validate all outcomes of 
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a model because independent external data cannot be easily found, especially in the case of new 
health technologies (e.g. immuno-oncology therapies) [17-18]. Another issue raised by this study was 
whether HTA agencies should provide specific guidelines on model validation. This will be addressed 
in the forthcoming update of the HAS guidelines on economic evaluation. 
3.2.  Experience of an ERG and NICE Committee member with models 
submitted by industry 
Model verification and validation by an independent group is an essential step in the appraisal 
process undertaken by the National Institute for Health and Care Excellence (NICE) [19]. There are 
two major reasons for this: first, models submitted to support reimbursement of health technologies 
can be complex and it is not surprising that mistakes are made in their construction; second, where 
two assumptions are equally plausible, it is common that the company whose product is under 
evaluation selects the assumption that is more favorable to their product. In this second 
circumstance, it can be argued that the company would be negligent to their shareholders if they did 
not take the option to position the intervention in a more positive light. As far back as 2005, [20] a 
review of multiple technology appraisals (MTAs) indicated that there was systematic bias in the 
incremental cost effectiveness ratio (ICERs) estimated by the submitting company compared with 
those estimated by the independent academic group, with the ICERs estimated by the company 
being systematically more favorable (p value <0.001).  
The NICE appraisal process has now largely moved to single technology appraisals (STAs). In STAs, in 
contrast to MTAs, the ERGs do not construct their own model but critique the evidence submitted by 
the company and make amendments, where possible, to the company model. Due to time 
constraints, however, it is common that the ERG only highlights structural limitations but does not 
amend the model. Based on the experience of one of the authors (MS), who is both an appraisal 
committee member and director of an ERG, the change to STAs has not altered the typical rank-
ordering of the company-submitted ICER and the ICER deemed most plausible by the ERG. One 
recent example of a model shown to be particularly favorable was the STA of azacytidine for acute 
myeloid leukemia [21], where the company’s ICER of approximately £21,000/QALY gained increased 
to approximately £63,000 when undisputed errors in the model construction were corrected; and 
incorporating further amendments resulted in an ERG-preferred ICER of about £273,000. Another 
example is regorafenib for previously treated advanced hepatocellular carcinoma [22], where the 
company’s initial submission resulted in a more favorable ICER because it did not pool data from two 
surveys as believed appropriate by the NICE cancer drugs fund committee and failed to mention one 
of these two surveys in their submission. Yet another recent example, is cenegermin for treating 
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neurotrophic keratitis where the NICE Appraisal Committee described the submitted model as 
“structurally flawed” and stated that the results “cannot be considered reliable” [23]. Numerous 
appraisals have been undertaken where the companies’ assumptions relating to the most 
appropriate survival curves have been judged to be too optimistic by NICE appraisal committees. It is 
clear from this experience that an independent assessment of a company’s model, particularly in the 
absence of credible validation, is essential. The exception is for interventions that are part of a class 
and which have similar costs and effectiveness as recommended comparators. In this instance, it 
should be the case that similar results are produced for each intervention regardless of the model 
structure, assumptions and parameter values. An example of this is golimumab for treating non-
radiographic axial spondyloarthritis [24]. 
3.3. View of a modeler working at a consulting company 
Building a model is always a challenge because it requires understanding enough of the complex 
process to be modeled to ensure that the simulation behaves in such a way that it corresponds 
reasonably well to reality. For HTA, this requires sufficient grasp of the intricacies of a disease and 
the effects of the interventions that may be implemented, some of which may be as yet poorly 
known. There is also the additional challenge that the context to be modeled is deliberately artificial. 
In the other fields from which HTA has borrowed modeling techniques (e.g., decision trees [25]; 
state-transition models [26]; dynamic transmission models [27], and system dynamics [28]) there is 
usually a real world against which to validate the model. This is obvious with weather forecasting, 
modeling of physical contexts like an airport luggage system, the integrity of a new airplane design, 
the trajectory of a missile, and so on. In HTA, however, the models simulate an idealized view of the 
world, where one or more of the following apply: 
 All patients start at time 0 
 There are no constrained resources, and thus no queues 
 All treatment options are instantly available 
 Variability is severely reduced 
 Physicians and patients behave optimally 
 Development of new interventions is frozen in time 
 Time horizons are well beyond the observable immediate future 
Without the real world as a validity check, and in the face of the often-conflicting demands of 
sponsors, good practice guidelines and tight timelines, HTA modeling must depend on following best-
practices for construction of the model, expressly verifying all of it, and validating as much of it as 
possible. Best practices for construction and verification include: 




 Not hiding anything 
 Minimizing the use of custom macros or bespoke software subroutines 
 Using pre-verified components (e.g., a standard module to select a death time from a 
specified distribution) as much as possible 
 Permitting users to change the inputs 
 Ensuring clear, detailed documentation (data decisions, sources, model structural choices, all 
assumptions and their consequences) 
Verification 
 Evaluating all equations separately to ensure that they are implemented correctly and yield 
expected results. If they feed values into each other the testing must cover this. 
 Careful checking of the implementation to ensure that the model behaves as intended and 
doesn’t have ‘bugs’ such as Markov leaks (when people disappear or reappear illogically) or 
event sequences happen in an impossible order.  
Regardless of how well best practices for construction and verification are followed, the need for 
validation remains paramount.  
Validation requires, at a minimum: 
 Testing the model against the datasets used to develop it. Although this is entirely 
dependent validation, it supports the careful verification. 
 Actively searching for independent data against which to validate model outputs. 
4. A pragmatic solution? 
In the preceding section, there is already the glimmer of a pragmatic solution. Following good 
practices will reduce the degree to which models are a “black box” and make it more difficult to 
present only those model implementations that favor a particular point of view. Increasing and 
formalizing efforts at verification [3] will decrease the flagrant errors and bolster confidence that the 
model is at least producing results consistent with its intended implementation. But, are these 
initiatives enough to bring about trust in those results? In the absence of a reality against which to 
validate, how do we get to a collective level of confidence that allows us to rely on the modeling 
results to inform the difficult decisions at issue in HTA? 
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The first step is for all involved to acknowledge that these models are not aiming to produce 
predictions for the real world. At best, the objective is to compare interventions in well-defined but 
artificial scenarios to get an idea of their potential cost-effectiveness. Once that is accepted, steps 
can be taken to ensure that the comparisons are not biased by choices made during construction or 
by failure to detect errors during verification. This requires that the modeling community stop 
reinventing the wheel—bespoke, product-specific models, including their parameterization, must 
become a thing of the past [3, 16].  
A far more efficient and confidence-building approach is to engage in producing standard modules 
that can be extensively verified individually. These should be well-documented and freely-available 
to any modeler to use in creating a model. Then, when assembling them to construct a new model it 
is only the assembly that needs to be tested—a much lower hurdle than verifying the entire model. 
This also implies that if all stakeholders, including the HTA agencies have approved the modules, 
some of the problems described in the previous sections would be minimized. 
De novo construction of models, even with pre-verified modules, should eventually become the 
exception, however [16]. For as many indications as possible, we need to progress to well-
established, detailed models that can handle most contexts, interventions, patient populations and 
other important variations. These standard models should leverage as many of the validated 
modules as feasible; and portions that require something new should be taken as a prompt for the 
addition of new modules to the common library. Needless to say, the resulting models should also be 
available to anyone who wants to use them. This is in line with recent calls for “open-source” models 
[29]. Having many eyes poring over the conceptualization, the structure, its implementation, and all 
other aspects of the model over broad periods of time has a much better chance of uncovering 
problems than the rushed verification typical of bespoke models. After Mozilla’s transition of its 
Firefox browser to open source, for example, more than 7,000 bugs were reported in the six months 
between releases of an updated version [30]. The salutary effect of knowing that one’s work will be 
closely scrutinized is also undeniable.  
This transition to open-source models should also substantially improve their validity, at least with 
respect to the objective of assessing potential cost-effectiveness.  By the very nature of open-source, 
the models will also be more generalizable, work for multiple interventions and allow for all relevant 
events. They should, as well, become more transparent and well-documented. With multiple 
modelers contributing, the risk of a model having to be shelved due to a key developer disappearing 
is also minimized. While open-source may increase trust in the results of model-based economic 
analyses, the academic community, HTA organizations and private companies face major challenges 
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in terms of funding construction of models, protecting commercial or academic “in confidence” data, 
as well as technical barriers to implementation of open source models (e.g., agreement on the 
programming language). 
Thus, until we move fully to open-source, we propose the following pragmatic steps to the vexing 
problem of trusting decision-analytic models intended for HTA: 
1. Construct the model using, to the extent possible, pre-verified standard modules.  
 Those aspects that cannot be modeled using standard modules should be used as the 
basis for developing new modules, which then undergo full verification. 
2. Build the model in incremental steps with documented checks of model behavior between 
each step.  
3. Predict what is expected from the next model step and review the results of the next round 
based on that prediction. 
4. Test the model against the datasets used to develop and document the tests. 
5. Seek independent data against which to validate model outputs and document the searches, 
results and validation exercises. 
6. Compare results against those of other models, if they exist, and try to explain any 
differences. 
7. Make models intended for supporting health-care decisions available to anyone who wishes 
to review them (possibly under a non-disclosure agreement). Specifically, provide: 
o All code, equations, data sources 
o All analyses 
 Base case 
 Uncertainty 
 Scenarios 
o Detailed technical report 
o Verification reports 
o Validation exercises.  
In addition, a standard platform for model implementation should be developed, perhaps under the 
auspices of a broadly representative consortium. These practical and feasible steps will make major 
strides in bolstering everyone’s trust in the results of model-based economic evaluations.  
Although not the subject of this paper, it should be noted that successful validation of economic 
models depends on access to data. Thus, data holders can contribute to trust in modeled results by 
permitting modelers to use their data in validation exercises. Moreover, data on a product's 
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effectiveness, especially longer term, are often lacking. This can only be remedied with extended 
data collection, and perhaps by leveraging large data sets.  
5. Conclusion 
In this paper, we have summarized the experiences with model validation and verification from 3 
differing viewpoints. It is clear that there is much progress to be made before models can be 
routinely trusted. We have suggested pragmatic steps which we believe would improve the validity 
of models. We are aware that their implementation not only will take time, but will also require a 
broad consensus among all public and private organizations using economic models for supporting 
health-care decisions.  
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